1887
Preview this article:
Zoom in
Zoomout

Emergence of nalidixic acid-resistant serovar Typhi resistant to ciprofloxacin in India, Page 1 of 1

| /docserver/preview/fulltext/jmm/56/1/136-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46763-0
2007-01-01
2019-11-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/1/136.html?itemId=/content/journal/jmm/10.1099/jmm.0.46763-0&mimeType=html&fmt=ahah

References

  1. Asna, S. M. & Haq, J. A. ( 2000; ). Decrease of antibiotic resistance in Salmonella typhi isolated from patients attending hospitals of Dhaka City over a 3 year period. Int J Antimicrob Agents 16, 249–251.[CrossRef]
    [Google Scholar]
  2. Asna, S. M., Haq, J. A. & Rahman, M. ( 2003; ). Nalidixic acid-resistant Salmonella enterica serovar typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 56, 32–33.
    [Google Scholar]
  3. Chiu, C. H., Wu, T. L., Su, L. H., Chu, C., Chia, J. H., Kuo, A. J., Chien, M. S. & Lin, T. Y. ( 2002; ). The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype cholerasuis. N Eng J Med 346, 413–419.[CrossRef]
    [Google Scholar]
  4. Hakanen, A., Kotilainen, P., Jalava, J., Siitonen, A. & Huovienen, P. ( 1999; ). Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 37, 3572–3577.
    [Google Scholar]
  5. Jesudason, M. V., Malathy, B. & John, T. J. ( 1996; ). Trends of increasing levels of minimum inhibitory concentration (MIC) of ciprofloxacin to Salmonella typhi. Ind J Med Res 103, 247–249.
    [Google Scholar]
  6. Kapil, A. R. & Das, B. ( 2002; ). Nalidixic acid susceptibility test to screen ciprofloxacin resistance in Salmonella typhi. Ind J Med Res 115, 49–54.
    [Google Scholar]
  7. Le Lostec, Z., Fegueux, S., Jouve, P., Cheron, M., Mornet, P. & Boisivon, A. ( 1997; ). Reduced susceptibility to quinolones in Salmonella typhi acquired in Europe: a clinical failure of treatment. Clin Microbiol Infect 3, 576–577.[CrossRef]
    [Google Scholar]
  8. Marimon, J. M., Goariz, M., Zigorraga, C., Cilla, G. & Perez-Trallero, E. ( 2004; ). Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003. Antimicrob Agents Chemother 3, 576–577.
    [Google Scholar]
  9. Mehta, G., Randhawa, V. S. & Mohapatra, N. P. ( 2001; ). Intermediate susceptibility to ciprofloxacin in Salmonella typhi strains in India. Eur J Clin Microbiol Infect Dis 20, 760–761.[CrossRef]
    [Google Scholar]
  10. Miller, S. I., Hohmann, E. L. & Pegues, D. A. ( 1995; ). Salmonella. In Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 4th edn, pp. 2013–2033. Edited by G. L. Mandell, E. Bennett & R. Dolin. New York: Churchill Livingstone.
  11. Murdoch, D. A., Banatvala, N. A., Bone, A., Shoismatulloev, B. I., Ward, L. R. & Threlfall, E. J. ( 1998; ). Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351, 339.[CrossRef]
    [Google Scholar]
  12. Threlfall, E. J. & Ward, L. R. ( 2001; ). Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi in the United Kingdom. Emerg Infect Dis 7, 448–450.[CrossRef]
    [Google Scholar]
  13. Threlfall, E. J., Ward, L. R., Skinner, J. A., Smith, H. R. & Lacey, S. ( 1999; ). Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 353, 1590–1591.[CrossRef]
    [Google Scholar]
  14. Threlfall, E. J., Skinner, J. A. S. & Ward, L. R. ( 2001; ). Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes typhi and paratyphi A. J Antimicrob Chemother 48, 740–741.[CrossRef]
    [Google Scholar]
  15. Wain, J., Hoa, N. T., Chinh, N. T., Vinn, H., Everett, M. J., Diep, T. S., Day, N. P., Solomon, T., White, N. J. & other authors ( 1997; ). Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 25, 1404–1410.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46763-0
Loading
/content/journal/jmm/10.1099/jmm.0.46763-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error